Forge Biologics Cleared for Clinical Trial of FBX-101, a Krabbe Disease Treatment

 

The FDA has recently cleared an Investigational New Drug (IND) application for FBX-101, allowing it to move into a Phase 1/2 clinical trial. This gene therapy was developed for the treatment of Krabbe disease, a severe form of pediatric leukodystrophy that is typically fatal by age two. As there is currently no approved treatment for this condition, this IND approval marks a large step in the right direction for patients.

Read in full:

https://patientworthy.com/2021/01/12/forge-biologics-cleared-trial-fbx101-krabbe-disease/

0/5 (0 Reviews)